PDE7A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28405	0.77	14/20
SCHEMBL99781	1.00	10/20
SCHEMBL100608	1.00	10/20
SCHEMBL100698	1.00	10/20
SCHEMBL100704	1.00	10/20
SCHEMBL100717	1.00	10/20
SCHEMBL100957	1.00	10/20
SCHEMBL101130	1.00	10/20
SCHEMBL139621	1.00	10/20
SCHEMBL100080	0.95	10/20
SCHEMBL100239	0.93	10/20
SCHEMBL100852	0.93	10/20
SCHEMBL100878	0.93	10/20
SCHEMBL138725	0.93	10/20
SCHEMBL99932	0.91	10/20
SCHEMBL100673	0.91	10/20
SCHEMBL100956	0.91	10/20
SCHEMBL100074	0.91	10/20
SCHEMBL100674	0.91	10/20
SCHEMBL100716	0.91	10/20

Clinical trials — most relevant to PDE7A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study	PHASE4	COMPLETED
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?	PHASE4	COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis	PHASE4	COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage	PHASE3	NOT_YET_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study	PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.	nan	UNKNOWN
Endurance Performance at Altitude	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia	nan	UNKNOWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children	nan	COMPLETED
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PDE7A binder may also engage these)

Protein	Name	Similarity
P70453	—	0.995	P70453 →
Q9QXQ1	—	0.990	Q9QXQ1 →
PDE7B	3',5'-cyclic-AMP phosphodiesterase 7B	0.988	landscape →
O08593	—	0.988	O08593 →
Q6DD21	—	0.967	Q6DD21 →
Q641K1	—	0.966	Q641K1 →
Q01066	—	0.965	Q01066 →
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	0.965	landscape →
MELK	Maternal embryonic leucine zipper kinase	0.965	landscape →
Q28GW8	—	0.965	Q28GW8 →
P98192	—	0.965	P98192 →
Q9UPU7	—	0.964	Q9UPU7 →
Q9UPW5	—	0.964	Q9UPW5 →
Q96MI9	—	0.963	Q96MI9 →
Q5R5S1	—	0.963	Q5R5S1 →
A9JRL3	—	0.963	A9JRL3 →
Q28CB1	—	0.963	Q28CB1 →
Q8N5V2	—	0.963	Q8N5V2 →
F1QGZ6	—	0.963	F1QGZ6 →
Q01061	—	0.963	Q01061 →
Q28156	—	0.962	Q28156 →
Q0GNC1	—	0.962	Q0GNC1 →
O94952	—	0.962	O94952 →
Q4U2V3	—	0.962	Q4U2V3 →
Q09M05	—	0.962	Q09M05 →
O43304	—	0.962	O43304 →
Q6NNF2	—	0.962	Q6NNF2 →
O77746	—	0.962	O77746 →
E1C3P4	—	0.962	E1C3P4 →
Q80VK6	—	0.962	Q80VK6 →